Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation

Abstract

Summary: In utero hematopoietic stem/progenitor cell transplantation (IUHSCT) has only been fully successful in the treatment of congenital immunodeficiency diseases. Using sheep as a large animal model of IUHSCT, we demonstrate that administration of CD146+CXCL12+VEGFR2+ or CD146+CXCL12+VEGFR2− cells prior to, or in combination with, hematopoietic stem/progenitor cells (HSC), results in robust CXCL12 production within the fetal marrow environment, and significantly increases the levels of hematopoietic engraftment. While in the fetal recipient, donor-derived HSC were found to reside within the trabecular bone, the increased expression of VEGFR2 in the microvasculature of CD146+CXCL12+VEGFR2+ transplanted animals enhanced levels of donor-derived hematopoietic cells in circulation. These studies provide important insights into IUHSCT biology, and demonstrate the feasibility of enhancing HSC engraftment to levels that would likely be therapeutic in many candidate diseases for IUHSCT. : Almeida-Porada and colleagues show that after in utero transplantation, donor-derived HSC locate within the trabecular bone of the metaphysis, and that manipulation of the fetal vascular marrow niche, through transplantation of CD146+CXCL12+VEGFR2+ cells, boosts HSC engraftment to levels that would be therapeutic in many diseases.